Telavancin (Theravance).

Abstract	Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram-positive bacterial infection. Phase III trials in complicated skin and skin structure infections commenced in September 2004.
Authors	John L Pace, J Kevin Judice
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 2 Pg. 216-25 (Feb 2005) ISSN: 1472-4472 [Print] England
PMID	15751746 (Publication Type: Journal Article, Review)
Chemical References	Aminoglycosides Lipoglycopeptides telavancin
Topics	Aminoglycosides (adverse effects, chemical synthesis, metabolism, pharmacokinetics, pharmacology, therapeutic use) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Contraindications Drug Evaluation, Preclinical Gram-Positive Bacterial Infections (drug therapy, microbiology) Lipoglycopeptides Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!